Categories: News

RESTEM to Participate in Jones Las Vegas Technology and Innovation Conference

MIAMI, April 01, 2025 (GLOBE NEWSWIRE) — RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced its participation in the Jones Las Vegas Technology and Innovation Conference, to be held April 8-9, 2025, at The Venetian Resort in Las Vegas, Nevada. Andres Isaias, Chief Executive Officer of RESTEM, will be presenting a corporate overview of the Company on Wednesday, April 9, 2025, at 11:00 a.m. PT, in a virtual format.

A live webcast of the presentation can be accessed here. A replay of the event will be available on the “Corporate Presentation” section of the RESTEM website after the conclusion of the event and will be archived on the RESTEM website at www.restem.com.

The Jones Conference is recognized for bringing together a select group of innovative companies and institutional investors for a two-day event. The event will be focused on one-on-one (1×1) meetings, fireside chats, panels, and networking.

For more information about the Jones Las Vegas Technology and Innovation Conference, including a list of participating companies, visit their B2i Digital Featured Conference page.

About RESTEM

RESTEM is a leading clinical-stage biotechnology company focused on developing off-the-shelf, next-generation cell therapies designed to modulate the immune system. Leveraging our proprietary products, robust clinical development expertise, and cutting-edge-manufacturing capabilities, we advance two potentially groundbreaking programs, Restem-L, our umbilical cord lining stem cells (ULSCs) program for auto-immune diseases and our natural killer cell (NK) therapeutics targeting senescence and age-associated disorders. Our therapies are intended to treat a broad range of disabling diseases and are designed to improve patient outcomes, as well as overall health and wellness. RESTEM is headquartered in Miami, Florida. For more information, please visit www.restem.com and follow us on X and LinkedIn.

Investor Contact

Daniel Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com

Media Contact

Nelson Cabautan
Restem Group, Inc.
+1.800.490.0924
ncabatuan@restem.com

Staff

Recent Posts

Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

10 minutes ago

AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

12 minutes ago

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

1 day ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

1 day ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

1 day ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

1 day ago